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be difﬁcult for patients with co-morbidities. To reduce these toxicities, 
we conducted a phase II study to evaluate the efﬁcacy and toxicity of 
weekly cisplatin and docetaxel in advanced NSCLC.
Methods: Eligibility included patients with advanced or recurrent 
NSCLC, ECOG PS of 0-1, and no prior chemotherapy for metastatic 
disease. This Cancer Institute of New Jersey network, single stage 
phase II clinical trial was designed to give 3 weekly doses of cisplatin 
at 25 mg/m2 and docetaxel at 35 mg/m2, followed by 1 week of rest, 
for a total of 6 cycles of therapy. Toxicity was monitored weekly, and 
disease evaluation was performed every 2 cycles. The primary endpoint 
was response rate (RR); secondary endpoints included time to progres-
sion (TTP), median and 1-year survival. 
Results: From 12/03 to 03/07, 38 patients were enrolled so far. The 
median age of patients is 63 (range 47-78), the majority is white 
(n=35), 31 have stage IV disease, and almost half (n=18) are women. 
Fifteen have an ECOG PS=0 and 23 with PS=1. Histologic subtypes 
are: adenocarcinoma (n=26), NSCLC NOS (n=7), squamous (n=5). 
Fourteen patients received ? 4 cycles of therapy; median number of 
cycles delivered is 2.4. Reasons for treatment discontinuation include 
completion of therapy (n=7), progression of disease (n=17), adverse 
events (n=8), and patient preference (n=4). Two patients continue on 
therapy at this time. No complete responses were yet observed; 8 pa-
tients (21%) achieved a partial response; 10 patients had stable disease, 
10 patients progressed, 8 came off study before ﬁrst disease evaluation, 
and 2 have not yet had disease evaluation. Median TTP was 3.8 months 
(mo) (95% CI 2.0, 4.7), median survival is 8.7 mo (95% CI 5.6,16.2) 
and 1-year survival is 40.2% (95% CI 20.9, 58.8). Most toxicities 
were mild but also included neutropenia (grade 3, n=1; grade 4, n=1), 
neutropenic fever (n=1), renal toxicity (grade 3, n=2), nausea (grade 
3, n=1), fatigue (grade 3, n=3), diarrhea (grade 3, n=4) and metabolic 
abnormalities (grade 3, n=3). 
Conclusion: Weekly cisplatin and docetaxel is well tolerated with a 
low incidence of toxicity and demonstrates activity similar to every 
3-week treatment in patients with advanced NSCLC.
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Background: Unitl 2004, docetaxel in monotherapy was the standard 
for second-line treatment of non-small cell lung cancer (NSCLC). 
Pemetrexed (P), an multi-target antifolate, with vitamin supplementa-
tion, has shown similar activity in this setting with a better adverse 
event proﬁle (Hanna N et al, J Clin Oncol 2004;22:1589-1597). In 
Portugal, it was introduced in October of 2004 for second-line mono-
therapy. We have carried out a retrospective analysis of patients who 
received P for second-line NSCLC in Portugal from October 2004 to 
December 2006.
Methods: Data were collected retrospectively from the records of 
patients (pts) enrolled in centers participating in the Portuguese Lung 
Cancer Study Group (GECP). The pts had locally advanced or meta-
static NSCLC and failed ﬁrst-line chemotherapy. They received P (500 
mg/m2 on a three-weekly schedule with vitamin supplementation). 
Objective response (OR; complete [CR] or partial [PR] response) was 
evaluated using RECIST and safety assessed using serious or non-seri-
ous adverse events (SAEs/AEs).
Results: By December 2006, 19 GECP centers had enrolled 244 
pts who had received P for ≥1 cycle, and were considered evaluable 
for both objective response and safety. Demography: male/female, 
175/69; median age, 57.0 years (range 20-81); smoking status, y/ex/n, 
116/57/71 adenocarcinoma/squamous-cell carcinoma/other histology, 
141/72/31; prior chemotherapy, platin plus gemcitabine/paclitaxel/
vinorelbine/docetaxel, 152/37/30/19; mean number of cycles in 1st 
line, 4.8 (range 1-8); disease control (OR + stable disease [SD]) was 
observed in 170 (61.0%) pts: 7 CR, 79 PR and 84 SD; mean time to 
progression (TTP) 8.07 months. P mean number of cycles in 2nd line, 
4.1 (range1-15); disease control in 209 evaluable pts was observed in 
116 (55.5%): 2 CR, 45 PR and 69 SD; mean TTP 4.70 months. The 
majority of AEs were grade 3 anemia (15 pts) and neutropenia (18 pts). 
The mean overall survival was 17.27 months.
Conclusions: Our retrospective analysis has observed a similar disease 
control rate with P in 2nd line (55.5%), and TTP (4.7 months) in our 
current unselected population to that published in the literature. P is an 
option for second-line NSCLC with a good tolerability.
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Background: Docetaxel (D) and Pemetrexed (P) are two options for 
the second-line treatment of non small-cell lung cancer (NSCLC), 
with similar response rates and overall survivals but different toxicity 
(Hanna N et al, J Clin Oncol 2004;22:1589-1597). P was introduced 
in Portugal in October 2004. The authors carried out a retrospective 
study of patients (pts) diagnosed with NSCLC treated in 2nd line with 
D or P at Portuguese Institute of Oncology - Porto Centre (IPO-Porto), 
Portugal.
Methods: We made a retrospective review of the pt clinical ﬁles with 
NSCLC treated in second-line with D or P between December 2003 
and December 2006 at IPO-Porto. The primary objective was the 
evaluation of safety assessed using serious or non-serious adverse 
events. Secondary objectives were to assess time to progression (TTP) 
and overall survival (OS) between the two drugs on that unselected 
population.
Results: Of 96 evaluated pts who received 2nd line chemotherapy 
(CT), 78% were male. Median age at diagnosis was 63 years (range: 
29-81); 38% were adenocarcinomas, 58% squamous cell carcinoma 
and 4% were large cell carcinomas; 99% had a performance status 
ECOG 0. At diagnosis, 50% had metastasis in at least one site. All pts 
received platin ﬁrst line based CT. At 2nd line treatment, 77 (80%) re-
ceived D and 19 (20%) P. Mean number of cycles received was 5.6 for 
D and 4.3 for P. The sum of grade III toxicities were observed on 27 pts 
on D and 7 on P, and grade IV toxicities were observed on 10 pts on D 
and none on P. Incidence of grade III anaemia was 12% on D and 11% 
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at P. Incidence of grade III and IV neutropenia was 9% on D and none 
on P. Incidence of grade III and IV respiratory infection was 12% on D 
and 5% on P. Median OS was 17.94 months (95%CI: 14.82-21.06) for 
D and 18.92 months (95%CI: 13.24-24.61) for P (p=0.849). Median 
TTP from 1st line was 7.36 months (95%CI: 6.46-8.26) for D and 5.55 
months (95%CI: 4.43-6.67) for P (p=0.080). Median TTP from 2nd line 
was 3.75 months (95%CI: 1.98-5.52) for D and 3.18 months (95%CI: 
0.44-5.94) for P (p= 0.520).
Conclusions: As published, these results shows on our unselected 
daily practice population with NSCLC, a similar TTP and OS using 
docetaxel or pemetrexed as 2nd line treatment, but this later drug op-
tion shows a clear more favourable safety proﬁle.
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Purpose: Gemcitabine (GEM) and Vinorelbine (VNR) have dem-
onstrated activity as a ﬁrst-line treatment in elderly patients with 
advanced non-small-cell lung cancer (NSCLC). We conducted a mul-
ticenter phase II trial to evaluate the efﬁcacy and toxicity of bi-weekly 
administration of gemcitabine plus vinorelbine in elderly patients with 
advanced NSCLC. 
Patients and methods: Forty-six chemotherapy-naive elderly (age: 70 
years or older) NSCLC patients were enrolled. Patients were eligible if 
they had histologically or cytologically conﬁrmed unresectable NSCLC 
with measurable and/or assessable disease. Patients received GEM 
(1000 mg/m2) and VNR (25 mg/m2) every 2 weeks. 
Results: The objective response rate of this treatment was 22.7% (95% 
Conﬁdence Interval (CI), 10.3-35.1%), median survival time was 310 
days, and median time to progression was 133 days. The one-year sur-
vival rate was 40.9% (95% CI, 26.3-55.4%), and most adverse events 
were mild. Only 3 (6.8%) patients needed to omit GEM because of 
grade 4 neutropenia or due to physician judgment. No patients suffered 
treatment-related death. 
Conclusions: Bi-weekly administration of gemcitabine plus vinorel-
bine in elderly patients was an effective, feasible and well-tolerated 
treatment schedule.
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Background: Docetaxel is active against chemotherapy-pretreated 
non-small-cell lung cancer (NSCLC). S-1 is a novel oral ﬂuoropyrimi-
dine, composed of tegafur, 5-chloro-2,4-dihydroxypyridine (dihydro-
pyrimidine dehydrogenase inhibitor), and potassium oxonate (orotate 
phosphoribosyl transferase inhibitor). It has been commercially avail-
able and used for NSCLC in Japan. We conducted this study to evaluate 
the efﬁcacy and safety of docetaxel combined with S-1 in NSCLC 
patients (pts) who were previously treated with one or more regimens.
Methods: Eligible pts were required to have histologically or cytologi-
cally conﬁrmed measurable or evaluable stage IIIB or IV NSCLC, age≥ 
20 years, one or more previous chemotherapy, a performance status 
(PS) 0-1, and adequate organ function and bone marrow reserve. In this 
study, pts received S-1 (80mg/m2 orally on days 1-14) and docetaxel 
(40mg/m2 IV on days 1). Treatment was repeated every 3 weeks.
Results: Between January 2005 and May 2006, 30 pts were enrolled on 
this study. 29 pts were eligible and evaluable. Median age was 67 (48-
79), male/female (23/6), PS 0/1 (9/20), stage IIIB/IV (7/22), and prior 
chemotherapy regimen 1/2/3 (23/4/2). 28 pts received a platinum-based 
chemotherapy. Response: PR=7(24%), SD=13, PD=7, NE=2. Median 
survival time was 10.2 months. Grade 3/4 toxicities (% of pts) were as 
follows: leukocytes 6/0 (20.6%), neutrophils 7/3 (34.4%), platelets 0/0, 
infection 0/1 (3.4%), fever 2/0 (6.9%), diarrhea 1/0 (3.4%), neurology 
0/1 (3.4%), and mucositis 1/0 (3.4%). There were no treatment-related 
deaths.
Conclusions: The combination of docetaxel and S-1 was effective with
acceptable toxicity in pts with previously treated NSCLC. These results 
warrant further investigations of this regimen a randomized controlled 
trial as a second-line treatment for NSCLC.
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Background: Primary and acquired resistance to chemotherapy have 
been primary determinants of poor outcome in pts with metastatic 
NSCLC. Our group has shown that non-cytotoxic dose of suramin 
(10-50 ?M) produces chemosensitization in multiple preclinical tumor 
models, including chemo-pretreated tumors. 
Methods: Platinum-pretreated pts with stage IIIB/IV NSCLC (no 
prior docetaxel or gemcitabine allowed, allowed prior suramin) were 
randomized to receive 3 cycles of docetaxel (75 mg/m2 IV over 1 h q 3 
wks) + suramin (Arm A) or gemcitabine (1250 mg/m2 IV over 30 min 
d 1 and 8 q 3 wks) + suramin (Arm B). Suramin was infused over 30 
min, 2.5 hr prior to the chemotherapy. Suramin dose was calculated us-
ing a previously established dosing nomogram: Dose in mg = FACTOR 
x (actual body surface area) 2. Factor was 125 for the ﬁrst dose, and, 
for subsequent doses, was adjusted based on the time elapsed since the 
previous dose. Pts received either Arm A or Arm B and, after radiologic 
evaluation at 9 weeks (3 cycles), pts showing objective response (CR/
PR) were continued on the same Arm until progressive disease (PD) at 
which time pts crossed over to the other Arm, whereas pts with stable 
or PD immediately crossed over to the other Arm. Radiologic evalua-
tion was repeated after 3 cycles of treatments.
